In May 2001, the world's first targeted drug, Gleevec, was approved for marketing, marking the treatment of chronic myelogenous leukemia (hereafter referred to as CML) using tyrosine kinase inhibitors (hereafter referred to as TKIs). Imatinib price is very afforable with Medixo Centre.
